Add to ORKGBackground Long-term therapies such as disease modifying therapy for Multiple Sclerosis (MS) demand high levels of medication adherence in order to reach acceptable outcomes. The objective of this study was to describe adherence to four disease modifying drugs (DMDs) among statutorily insured patients within two years following treatment initiation. These drugs were interferon beta-1a i.m. (Avonex), interferon beta-1a s.c. (Rebif), interferon beta-1b s.c. (Betaferon) and glatiramer acetate s.c. (Copaxone). Methods This retrospective cohort study used pharmacy claims data from the data warehouse of th
Background: Low adherence to treatment in Multiple Sclerosis (MS) has been shown to lead to poor hea...
Background and Aims: In multiple sclerosis (MS), non-adherence/non-persistence is related to subopti...
Background: Adherence to interferon b-1b (INFb-1b) therapy is essential to maximize the beneficial e...
Long-term therapies such as disease modifying therapy for Multiple Sclerosis (MS) demand high levels...
Long-term therapies such as disease modifying therapy for Multiple Sclerosis (MS) demand high levels...
Journal Article; Research Support, Non-U.S. Gov't;BACKGROUND Adherence to interferon β-1b (INFβ-1b)...
textabstractBackground: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of t...
Copyright © 2014 G. Di Battista et al. This is an open access article distributed under the Creative...
PURPOSE: To describe drug-use patterns in patients with multiple sclerosis (MS) using disease-modify...
BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central n...
Introduction. Multiple sclerosis is an inflammatory demyelinating disease of the central nervous sys...
Disease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability i...
Background: Low adherence to treatment in Multiple Sclerosis (MS) has been shown to lead to poor hea...
Rachel Halpern1, Sonalee Agarwal2, Carole Dembek2, Leigh Borton1, Maria Lopez-Bresnahan31Health Econ...
Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't;OBJECTIVES To ...
Background: Low adherence to treatment in Multiple Sclerosis (MS) has been shown to lead to poor hea...
Background and Aims: In multiple sclerosis (MS), non-adherence/non-persistence is related to subopti...
Background: Adherence to interferon b-1b (INFb-1b) therapy is essential to maximize the beneficial e...
Long-term therapies such as disease modifying therapy for Multiple Sclerosis (MS) demand high levels...
Long-term therapies such as disease modifying therapy for Multiple Sclerosis (MS) demand high levels...
Journal Article; Research Support, Non-U.S. Gov't;BACKGROUND Adherence to interferon β-1b (INFβ-1b)...
textabstractBackground: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of t...
Copyright © 2014 G. Di Battista et al. This is an open access article distributed under the Creative...
PURPOSE: To describe drug-use patterns in patients with multiple sclerosis (MS) using disease-modify...
BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central n...
Introduction. Multiple sclerosis is an inflammatory demyelinating disease of the central nervous sys...
Disease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability i...
Background: Low adherence to treatment in Multiple Sclerosis (MS) has been shown to lead to poor hea...
Rachel Halpern1, Sonalee Agarwal2, Carole Dembek2, Leigh Borton1, Maria Lopez-Bresnahan31Health Econ...
Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't;OBJECTIVES To ...
Background: Low adherence to treatment in Multiple Sclerosis (MS) has been shown to lead to poor hea...
Background and Aims: In multiple sclerosis (MS), non-adherence/non-persistence is related to subopti...
Background: Adherence to interferon b-1b (INFb-1b) therapy is essential to maximize the beneficial e...
